Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluoroazomycin arabinoside F-18 is a radiofluorinated 2-nitroimidazole derivative used as a positron emission tomography (PET) imaging agent for detecting hypoxic tissue, particularly in tumors. Under hypoxic conditions, the compound is reduced to a reactive species that covalently binds to intracellular macromolecules, allowing for quantitative imaging of viable hypoxic cells. Compared to other tracers like 18F-misonidazole, it has improved pharmacokinetics with faster renal clearance and less accumulation in lipophilic tissues. It is under clinical investigation for use in various cancers including pancreatic ductal cancer, head and neck cancer, lung cancer, prostate cancer, and rectal cancer[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fluoroazomycin arabinoside F-18.